Short answer: Eight drugs are at issue in the federal stomach-injury MDL: Ozempic, Wegovy, Rybelsus, Victoza and Saxenda made by Novo Nordisk, and Trulicity, Mounjaro and Zepbound made by Eli Lilly. The court’s August 15, 2025 opinion lists all eight.
All are GLP-1 receptor agonists (Mounjaro and Zepbound also act on a second hormone, GIP). They slow how fast the stomach empties, which helps blood sugar and appetite but is also the basis of the injury claims.
- Wegovy lawsuit: same MDL and same claims as Ozempic, because both are semaglutide.
- Mounjaro and Zepbound lawsuits: tirzepatide claims against Eli Lilly in the same MDL.
- Compounded semaglutide: pharmacy-made versions are not made by these defendants, so they raise different questions.
- Vision loss: NAION claims go to a separate MDL, 3163.
Not sure which drug you were given? Your pharmacy record will show it. A free, confidential case review can help.
SourcesRule 702 opinionE.D. Pa., 15 Aug 2025CMO No. 18E.D. Pa., MDL 3094MDL 3163 transfer orderJPML, 15 Dec 2025


